SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and community debate as investors react to mixed signals regarding institutional activity, potential geopolitical de-escalation, and growing concerns about the long-term impact of quantum computing on crypto security. Market participants are actively split between those calling for a structural breakdown toward lower support levels and bulls who view current price action as a necessary consolidation before a potential squeeze.

Sidus Space, Inc. is a space-as-a-service company. The firm focuses on commercial satellite design, manufacture, launch planning, mission operations and in-orbit support, and data collection with a vision to demonstrate space operations for new technologies, and deliver data and predictive analytics to both domestic and global customers. The company was founded by Carol M. Craig on July 17, 2012 and is headquartered in Merritt Island, FL.

Sidus Space Inc - Ordinary Shares - Class A

Sidus Space is trending as investors aggressively accumulate shares ahead of potential SpaceX IPO catalysts, with community members closely tracking technical support levels and high institutional volume as signs of an imminent breakout. Discussion is heavily focused on the company's positioning in the orbital data and edge AI sectors, with many market participants viewing current price levels as a strategic entry point for long-term space sector growth.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors rally behind significant federal funding announcements, with the U.S. government entering letters of intent for investment stakes in several quantum firms. The community is actively debating whether this sector-wide momentum represents a fundamental shift in national tech infrastructure or a speculative pump based on high-risk, pre-revenue business models.

Hyliion Holdings Corp. engages in the development of sustainable electricity-producing technology. It focuses on providing modular power plant technology that can operate on various fuel sources through the KARNO power module. The company was founded by Thomas J. Healy in 2015 and is headquartered in Cedar Park, TX.

Hyliion Holdings Corporation - Ordinary Shares - Class A

Hyliion Holdings Corp

Hyliion Holdings is experiencing a significant surge in momentum driven by intense community speculation surrounding the potential of its KARNO power generation technology to serve as a critical infrastructure solution for AI data centers and military applications. Investors are closely monitoring upcoming milestones, including certification progress and potential commercial partnerships, while engaging in active discussions about the stock's positioning as a key play in the energy-demand narrative.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending following a government funding initiative that spurred intense market volatility, with the community actively debating whether this represents a long-term shift toward quantum infrastructure or a short-term speculative bubble ripe for a reversal. Traders are locked in a fierce battle between bullish sentiment regarding government backing and bearish concerns over extreme valuation, potential share dilution, and profit-taking ahead of the long holiday weekend.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is surging as investors react to a strategic U.S. government initiative providing federal funding and equity stakes, signaling a shift toward treating quantum technology as critical national infrastructure. The community is actively debating the stock's long-term valuation potential compared to sector peers, with many highlighting its neutral-atom technology and lack of debt as key differentiators.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is seeing increased retail chatter as investors highlight a combination of high short interest and a shrinking float driven by ongoing corporate share buybacks. The community is actively discussing the potential for a short squeeze, likening the setup to other historically volatile stocks while monitoring key price levels and upcoming earnings for signs of a breakout.

PicoCELA, Inc. engages in the manufacturing, installation, and services for enterprise wireless mesh solutions. It also offers wireless multi-hop relay devices. The company was founded by Hiroshi Furukawa on August 8, 2008 and is headquartered in Tokyo, Japan.

PicoCELA Inc - ADR

PicoCELA is drawing significant trader attention due to high volatility and aggressive momentum as a low-float play, with the community actively debating whether it is a legitimate breakout or a speculative pump-and-dump. Traders are closely monitoring key support levels and volume shifts, noting that similar Japanese micro-cap stocks are often being traded as a thematic basket alongside this symbol.

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Akari Therapeutics Plc - ADR

Akari Therapeutics

Akari Therapeutics is trending as traders react to positive preclinical data involving its ADC platform in pancreatic cancer models, combined with a recent strategic partnership to advance the program. The community is actively discussing its status as a high-volatility, low-float biotech play, with debates centered on the potential for massive percentage gains versus concerns regarding historical dilution and long-term clinical timelines.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is experiencing significant volatility as market participants debate whether the stock is undergoing routine post-earnings consolidation or sustained institutional manipulation. While bulls highlight stellar fundamentals and dividend increases as reasons to accumulate on the dip, frustrated retail traders are venting about the stock's underperformance compared to sector peers and are expressing anxiety over holiday weekend geopolitical risks.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates

Aligos shares rise after China licensing deal for HBV drug; milestones, trial updates, and technical levels shape investor outlook.read more...

This Micro Cap Biotech Stock Is Tracking Its Biggest Intraday Gains In 11 Months – Here’s Why A China Deal Has Retail Buzzing

Equity

Aligos Therapeutics announced a licensing deal with Xiamen Amoytop Biotech to develop and commercialize its hepatitis B drug candidate in Greater China.

Aligos Therapeutics Earnings Report: Q4 Overview

A Peek at Aligos Therapeutics's Future Earnings

Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 4.5% - Time to Sell?

Aligos Therapeutics (NASDAQ:ALGS) Trading Down 4.5% - Here's What Happened...

Does Aligos Therapeutics (ALGS) Have the Potential to Rally 737.74% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 737.7% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study

Rocket Pharmaceuticals' shares soar as the FDA lifts its clinical hold on the pivotal Danon disease gene therapy study.

Wall Street Analysts Predict a 983.24% Upside in Aligos Therapeutics (ALGS): Here's  What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 983.2% in Aligos Therapeutics (ALGS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Allogene's Q2 Loss Narrower Than Expected, Pipeline in Focus

ALLO posts a narrower second-quarter 2025 loss. The company advances multiple CAR T programs targeting cancer and autoimmune diseases.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Current Price	$5.77
Prev Close	$5.71
Open	$5.80
Dividend Yield	0.00%
50-Day Moving Average	$6.85
Beta	1.93
Avg. Volume	418,680.89
PE Ratio	-0.66

52-Week High	$13.69
52-Week Low	$5.12
Market Capitalization	$35.33M
EPS (Annual)	-$2.45
Price to Book	1.11
Revenue Per Employee	$26,658.54

ALGS
Aligos Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest ALGS News

ALGSAligos Therapeutics Inc